Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:00:55.997Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:00:55.997Z.
Quote observation: 2026-10-06T15:00:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
FORWARD PE RATIO
N/A
ADARx Pharmaceuticals, Inc.
Market Cap
$1.92B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| ADARx Pharmaceuticals, Inc. (ADRX) | $1.92B | N/A |
| Midera Food Processing, Inc. (MFP)vs › | $1.92B | 19.67 |
| Enerpac Tool Group Corp. (EPAC)vs › | $1.86B | 17.48 |
| Werner Enterprises, Inc. (WERN)vs › | $1.98B | 29.10 |
| Cimpress plc (CMPR)vs › | $1.82B | 15.04 |
| Arxis, Inc. Class A Common Stock (ARXS)vs › | $2.01B | 102.70 |
| Allient Inc. (ALNT)vs › | $2.01B | 43.28 |
| Neutron Holdings, Inc. (LIME)vs › | $1.79B | N/A |
| Trinity Industries, Inc. (TRN)vs › | $2.06B | 11.60 |
| Preformed Line Products Company (PLPC)vs › | $2.07B | 31.93 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
